NSABP FB-10 Phase II
NSABP FB-10-B
A Phase 1B/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DMI) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer
Protocol Chair: Jame Abraham, MD
Protocol Officer: Shannon Puhalla, MD
Patient Population:
Patients with metastatic HER2-positive breast cancer
Target Accrual: 22 patients
Status: Closed
ClinicialTrials.gov Identifier: NCT02236000
A Phase 1B/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DMI) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer
Protocol Chair: Jame Abraham, MD
Protocol Officer: Shannon Puhalla, MD
Patient Population:
Patients with metastatic HER2-positive breast cancer
Target Accrual: 22 patients
Status: Closed
ClinicialTrials.gov Identifier: NCT02236000